Advanced Prostate Cancer

Advanced Prostate Cancer/

Chemotherapy After Radium-223 Appears to be Safe in Men with Metastatic Castration-Resistant Prostate Cancer


Understanding how to best sequence and combine our new drugs to treat advanced prostate cancer includes the most discussed issue, efficacy. We want to know if a special order or a special combination of the approved drugs will nake a difference in both our quality of life (QoL) as well as how survival. Often left out of this conversation is safety, will the order we take our drugs or in what combination affect the our safety? We know that many of our new drugs cause cross-resistance to the next drug, however we rarely ask about the potential toxic effects that […]

Abiraterone Is Effective In Men Over 75 Years Who Are Chemotherapy-Naive And Have mCRPC

We know that Abiraterone (Zytiga) extends life, but we also know that its side effects can be harsh, especially in elderly men (men over 75 years). We also know that men with metastatic, castrate resistant prostate cancer (mCRPC) have a limited potential life expectancy. Given these facts, it is important to know if, despite being an elderly man, you can still receive a life extending benefit from taking Abiraterone.

In a post hoc analysis of the important COU-AA-302 trial researchers investigated the safety and efficacy of abiraterone in both elderly 75 years old or more ) and younger (less than 75 […]

Understanding and Trying to Rectify the Abusive Costs of Our Drugs

I have been relatively quiet about the skyrocketing cost of drugs, but it has now become impossible to remain out of the fray.

A Pharmaceutical company recently acquired a drug called Daraprim, the drug treats potentially fatal parasitic infections.   After its acquisition the company raised the price of Daraprim by almost 5,0000%. When confronted with great anger about the price increase, the company at first declined to comment until their CEO answered critics with a series of dismissive tweets and interviews.  The price of Daraprim remains out of reach for many individuals.

As we all know there are many drugs that have […]

Radium-223 When Given In Combinations May Improve Survival in mCRPC

As I have said before, the next big step in the clinical care of men with prostate cancer will be in not in the development of a new drug, but in our growing knowledge of how to sequence and combine our new drugs. Today’s post provides just one example of this new type of breakthrough we can look forward to in the near future.

In a recently released phase IIIb study of Radium-223 dichloride (Xofigo) that was given with concomitant medication, there was an improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) who also had bone […]